Wedoany.com Report-Nov. 25, AstraZeneca has unveiled a $2 billion investment to expand its manufacturing presence in Maryland, United States. The plan includes a major upgrade of its biologics facility in Frederick and construction of a new clinical manufacturing site in Gaithersburg.

The Frederick expansion will nearly double commercial production capacity for biologics used in cancer, autoimmune, respiratory, and rare disease treatments. For the first time, the site will also manufacture medicines from AstraZeneca’s rare disease portfolio. The project is scheduled to become operational in 2029 and will create 200 permanent skilled positions and approximately 900 construction jobs.

Simultaneously, a new state-of-the-art clinical supply facility in Gaithersburg will support development and trial production of innovative molecules. Also due for completion in 2029, it will add 100 permanent roles, retain 400 existing positions, and generate around 1,000 construction-related construction jobs.

Both facilities will incorporate advanced AI, automation, and data analytics while adhering to high environmental standards.

Maryland Governor Wes Moore stated: "AstraZeneca's commitment to Maryland speaks to our unique, world-class biotech ecosystem. This landmark investment affirms our reputation as a global leader in life sciences, while strengthening the U.S. medicine supply chain, accelerating the development of life-saving therapies, and creating hundreds of jobs. We are proud to partner with AstraZeneca to grow our economy and build new pathways to work, wages, and wealth for all."

Pascal Soriot, Chief Executive Officer of AstraZeneca, said: "Today marks a landmark moment for Maryland and American patients. As the state's largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland – supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the US medicines supply chain and accelerates access to transformative therapies for patients across America and around the world."

The Maryland announcement forms part of AstraZeneca's previously disclosed $50 billion investment programme across the United States and follows recent commitments including a new cell therapy facility in Rockville, Maryland, a drug substance plant in Virginia, and expansion in Coppell, Texas.

The United States represents AstraZeneca's largest market by revenue, with 19 research, manufacturing, and commercial sites nationwide. The company employs over 25,000 people in the country and supports more than 100,000 jobs overall, contributing approximately $20 billion to the U.S. economy in 2025.